Antibodies that target the glycan cap epitope on the ebolavirus glycoprotein (GP) are common in the adaptive response of survivors. A subset is known to be broadly neutralizing, but the details of their epitopes and basis for neutralization are not well understood. Here, we present cryoelectron microscopy (cryo-EM) structures of diverse glycan cap antibodies that variably synergize with GP base-binding antibodies. These structures describe a conserved site of vulnerability that anchors the mucin-like domains (MLDs) to the glycan cap, which we call the MLD anchor and cradle. Antibodies that bind to the MLD cradle share common features, including use of IGHV1-69 and IGHJ6 germline genes, which exploit hydrophobic residues and form β-hairpin s...
SummaryThe filoviruses, including Marburg and Ebola, express a single glycoprotein on their surface,...
Ebola virus is the etiological agent of a severe hemorrhagic fever with a high mortality rate. As th...
SummaryThe mechanisms by which neutralizing antibodies inhibit Marburg virus (MARV) are not known. W...
Antibodies that target the glycan cap epitope on ebolavirus glycoprotein (GP) are common in the adap...
Recent studies suggest that some monoclonal antibodies (mAbs) specific for ebolavirus glycoprotein (...
The envelope glycoprotein GP of the ebolaviruses is essential for host cell entry and the primary ta...
ABSTRACT Only one naturally occurring human antibody has been described thus far that is capable of ...
Summary: Monoclonal antibodies (mAbs) with pan-ebolavirus cross-reactivity are highly desirable, but...
SummaryPrevious efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS)...
Ebola virus (EBOV) in humans causes a severe illness with high mortality rates. Several strategies h...
AbstractHuman Ebola virus causes severe hemorrhagic fever disease with high mortality and there is n...
ABSTRACT Ebola virus (EBOV) entry requires the virion surface-associated glycoprotein (GP) that is c...
Summary: Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RB...
Ebola virus (EBOV) is the cause of sporadic outbreaks of human hemorrhagic disease in Africa, and th...
Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that...
SummaryThe filoviruses, including Marburg and Ebola, express a single glycoprotein on their surface,...
Ebola virus is the etiological agent of a severe hemorrhagic fever with a high mortality rate. As th...
SummaryThe mechanisms by which neutralizing antibodies inhibit Marburg virus (MARV) are not known. W...
Antibodies that target the glycan cap epitope on ebolavirus glycoprotein (GP) are common in the adap...
Recent studies suggest that some monoclonal antibodies (mAbs) specific for ebolavirus glycoprotein (...
The envelope glycoprotein GP of the ebolaviruses is essential for host cell entry and the primary ta...
ABSTRACT Only one naturally occurring human antibody has been described thus far that is capable of ...
Summary: Monoclonal antibodies (mAbs) with pan-ebolavirus cross-reactivity are highly desirable, but...
SummaryPrevious efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS)...
Ebola virus (EBOV) in humans causes a severe illness with high mortality rates. Several strategies h...
AbstractHuman Ebola virus causes severe hemorrhagic fever disease with high mortality and there is n...
ABSTRACT Ebola virus (EBOV) entry requires the virion surface-associated glycoprotein (GP) that is c...
Summary: Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RB...
Ebola virus (EBOV) is the cause of sporadic outbreaks of human hemorrhagic disease in Africa, and th...
Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that...
SummaryThe filoviruses, including Marburg and Ebola, express a single glycoprotein on their surface,...
Ebola virus is the etiological agent of a severe hemorrhagic fever with a high mortality rate. As th...
SummaryThe mechanisms by which neutralizing antibodies inhibit Marburg virus (MARV) are not known. W...